Balance of antiangiogenic and angiogenic factors in the context of the etiology of preeclampsia

Acta Obstetricia et Gynecologica Scandinavica

Volumn 93, Issue 10, 2014, Pages 959-964

  Seki, Hiroyuki ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Antiangiogenic factors; Etiology; Preeclampsia; Seng; Sflt 1; Trophoblasts; Two stage disorder

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ENDOGLIN; PLACENTAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; FLT1 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PLACENTA PROTEIN; VASCULOTROPIN A;

CLINICAL EVALUATION; HUMAN; PATHOPHYSIOLOGY; PREECLAMPSIA; PROTEIN EXPRESSION; REVIEW; SYNCYTIOTROPHOBLAST; THEORY; FEMALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATIENT ACUITY; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; VASCULARIZATION;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANTIGENS, CD; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PATIENT ACUITY; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; RECEPTORS, CELL SURFACE; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84908103889     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/aogs.12473     Document Type: Review

References (25)

1. Sibai BM, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785-99.
2. Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia. Semin Nephrol. 2011;31:33-46.
3. Roberts JM. Preeclampsia: what we know and what we do not know. Semin Perinatol. 2000;4:24-8.
4. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta. 2009;30 (Suppl A):S32-7.
5. Redman CWG, Tannetta DS, Dragovic RA, Gardiner C, Southcombe JH, Collett GP, et al. Review: does size matter? Placental debris and the pathophysiology. Placenta. 2012;33(Suppl. A):S48-54.
6. Wang A, Rana S, Karumanchi SA. Preeclampsia: The role of angiogenic factors in its pathogenesis. Physiology. 2009;24:147-58.
7. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992-1005.
8. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-83.
9. Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol. 2004;5:266-71.
10. Lash GE, Robson SC, Bulmer JN. Review: functional role of uterine natural killer (uNK) cells in human early pregnancy decidua. Placenta. 2010;24:S87-92.
11. Roberts JM, Gammill HS. Preeclampsia: recent insights. Hypertension. 2005;46:1243-9.
12. Guller S, Tang Z, Ma YY, Di Santo S, Sager R, Schneider H. Protein composition of microparticles shed from human placenta during placental perfusion: potential role in angiogenesis and fibrinolysis in preeclampsia. Placenta. 2011;32:63-9.
13. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade- Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484-96.
14. Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, Schaarschmidt W, et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation. 2011;124:940-50.
15. Seki H. The role of the renin-angiotensin system in the pathogenesis of preeclampsia - new insights into the renin-angiotensin system in preeclampsia. Med Hypotheses. 2014;82:362-7.
16. Stettler RW, Cunningham FG. Natural history of chronic proteinuria complicating pregnancy. Am J Obstet Gynecol. 1992;167:1219-24.
17. Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013;33:8-15.
18. Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Physiol. 2002;160:1405-23.
19. Jarvenpaa J, Vuoristo JT, Savolainen ER, Ukkola O, Vaskivuo T, Ryynanen M. Altered expression of angiogenesis-related placental genes in pre-eclampsia associated with intrauterine growth restriction. Gynecol Endocrinol. 2007;23:351-5.
20. Ranheim T, Staff AC, Henriksen T. VEGF mRNA is unaltered in decidua and placental tissues in preeclampsia at delivery. Acta Obstet Gynecol Scand. 2001;80:93-8.
21. Chung JY, Song Y, Wang Y, Magness RR, Zheng J. Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies. J Clin Endocrinol Metab. 2004;89:2484-90.
22. Shibuya M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem. 2013;153:13-9.
23. Lim JH, Kim SY, Park SY, Lee MH, Yang JH, Kim MY, et al. Soluble endoglin and transforming growth factor-b1 in women who subsequently developed preeclampsia. Prenat Diagn. 2009;29:471-6.
24. Mahasreshti PJ, Kataram M, Wang MH, Stockard CR, Grizzle WE, Carey D, et al. Intravenous delivery of adenovirus-mediated soluble Flt-1 results in liver toxicity. Clin Cancer Res. 2003;9:2701-10.
25. Kumasawa K, Ikawa M, Kidoya H, Hasuwa H, Saito-Fujita T, Morioka Y, et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci USA. 2011;108:1451-5.